Company Description
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need.
Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.
Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023.
The company was incorporated in 2009 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2009 |
| IPO Date | Apr 5, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Carmine Stengone |
Contact Details
Address: 10578 Science Center Drive, Suite 200 San Diego, California 92121 United States | |
| Phone | (858) 333-5280 |
| Website | contineum-tx.com |
Stock Details
| Ticker Symbol | CTNM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001855175 |
| ISIN Number | US21217B1008 |
| Employer ID | 27-1467257 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Carmine N. Stengone MBA, MS | President, Chief Executive Officer, Secretary and Director |
| Peter T. Slover CPA | Chief Financial Officer |
| Dr. Daniel S. Lorrain Ph.D. | Chief Science Officer |
| Morgan Paulsen | Senior Manager of Accounting |
| John Healy | General Counsel and Corporate Secretary |
| Dr. Stephen L. Huhn F.A.A.P, F.A.C.S., M.D. | Chief Medical Officer and Senior Vice President of Clinical Development |
| Austin Chen Ph.D. | Senior Vice President and Head of Research |
| Michael Mayberry | Senior Director and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 31, 2024 | SCHEDULE 13G | Filing |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| Aug 14, 2024 | 8-K/A | [Amend] Current report |
| Aug 13, 2024 | 8-K | Current Report |
| Jun 24, 2024 | 8-K | Current Report |
| May 31, 2024 | 8-K | Current Report |
| May 20, 2024 | 8-K | Current Report |
| May 16, 2024 | 10-Q | Quarterly Report |
| May 16, 2024 | 8-K | Current Report |
| Apr 15, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |